Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hold tight with your shares. European results will be coming along. Must be positive otherwise why would this grant pop out of no where?
Hit $9.23 as a high in pre market
BVXV hit $8 in premarket. up 40% Amazing.
Pre market volume US 596,218 shares http://www.nasdaq.com/symbol/bvxv/premarket?page=2
The TASE is up 40% already.
BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
PR Newswire PR NewswireMarch 30, 2017
http://finance.yahoo.com/news/biondvax-approved-grant-israels-ministry-060000803.html
NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959.
BiondVax plans to build the mid-sized factory in Jerusalem, with potential capacity to annually produce up to tens of millions of doses of M-001. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.
Dr. Ron Babecoff, BiondVax's CEO, commented, "This significant milestone signifies the evolution of BiondVax from a biotech start-up to a pharmaceutical company positioned for significant growth and contributions to society. I would like to thank the Ministry of Economy and Industry for helping translate BiondVax's vision to reality."
Dr. Shimon Hassin, BiondVax's COO noted, "In the past few years BiondVax focused on establishing a small scale GMP facility, one that was approved by the European Union. Our current facility laid the foundation for manufacturing quality excellence that will be implemented in the new factory."
An ongoing Phase 2b trial is being conducted in collaboration with the UNISEC consortium. The research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012. Positive preliminary safety results were announced[1] in November 2016. BiondVax's consortium partners are continuing to analyze study samples. BiondVax expects the consortium will finalize and release results in Q2 2017.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.
--------------------------------------------------
OMG! I never heard of any money being giving for a production facility prior to approval. Totally absurd and unbelievably fantastic.
BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
PR Newswire PR NewswireMarch 30, 2017
http://finance.yahoo.com/news/biondvax-approved-grant-israels-ministry-060000803.html
NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959.
BiondVax plans to build the mid-sized factory in Jerusalem, with potential capacity to annually produce up to tens of millions of doses of M-001. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.
Dr. Ron Babecoff, BiondVax's CEO, commented, "This significant milestone signifies the evolution of BiondVax from a biotech start-up to a pharmaceutical company positioned for significant growth and contributions to society. I would like to thank the Ministry of Economy and Industry for helping translate BiondVax's vision to reality."
Dr. Shimon Hassin, BiondVax's COO noted, "In the past few years BiondVax focused on establishing a small scale GMP facility, one that was approved by the European Union. Our current facility laid the foundation for manufacturing quality excellence that will be implemented in the new factory."
An ongoing Phase 2b trial is being conducted in collaboration with the UNISEC consortium. The research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012. Positive preliminary safety results were announced[1] in November 2016. BiondVax's consortium partners are continuing to analyze study samples. BiondVax expects the consortium will finalize and release results in Q2 2017.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.
--------------------------------------------------
BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
PR Newswire PR NewswireMarch 30, 2017
http://finance.yahoo.com/news/biondvax-approved-grant-israels-ministry-060000803.html
NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959.
BiondVax plans to build the mid-sized factory in Jerusalem, with potential capacity to annually produce up to tens of millions of doses of M-001. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.
Dr. Ron Babecoff, BiondVax's CEO, commented, "This significant milestone signifies the evolution of BiondVax from a biotech start-up to a pharmaceutical company positioned for significant growth and contributions to society. I would like to thank the Ministry of Economy and Industry for helping translate BiondVax's vision to reality."
Dr. Shimon Hassin, BiondVax's COO noted, "In the past few years BiondVax focused on establishing a small scale GMP facility, one that was approved by the European Union. Our current facility laid the foundation for manufacturing quality excellence that will be implemented in the new factory."
An ongoing Phase 2b trial is being conducted in collaboration with the UNISEC consortium. The research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012. Positive preliminary safety results were announced[1] in November 2016. BiondVax's consortium partners are continuing to analyze study samples. BiondVax expects the consortium will finalize and release results in Q2 2017.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.
--------------------------------------------------
BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
PR Newswire PR NewswireMarch 30, 2017
http://finance.yahoo.com/news/biondvax-approved-grant-israels-ministry-060000803.html
NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax's universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959.
BiondVax plans to build the mid-sized factory in Jerusalem, with potential capacity to annually produce up to tens of millions of doses of M-001. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.
Dr. Ron Babecoff, BiondVax's CEO, commented, "This significant milestone signifies the evolution of BiondVax from a biotech start-up to a pharmaceutical company positioned for significant growth and contributions to society. I would like to thank the Ministry of Economy and Industry for helping translate BiondVax's vision to reality."
Dr. Shimon Hassin, BiondVax's COO noted, "In the past few years BiondVax focused on establishing a small scale GMP facility, one that was approved by the European Union. Our current facility laid the foundation for manufacturing quality excellence that will be implemented in the new factory."
An ongoing Phase 2b trial is being conducted in collaboration with the UNISEC consortium. The research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012. Positive preliminary safety results were announced[1] in November 2016. BiondVax's consortium partners are continuing to analyze study samples. BiondVax expects the consortium will finalize and release results in Q2 2017.
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.
--------------------------------------------------
1. http://www.biondvax.com/2016/11/biondvax-phase-2b-trial-preliminary-safety-results-the-universal-flu-vaccine-candidate-is-safe-and-well-tolerated/
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the timing and pace of actual receipt of awards, our ability to satisfy conditions to receive the award, adequacy of cash resources generally and specifically to support the construction of the manufacturing facility, the ability to raise captal to support business plan and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.
For further information, please contact:
BiondVax
Joshua Phillipson
Business Development Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com
If I have the TASE correct. 54 Israeli Shekel, but that equals $14.92 US
http://www.tase.co.il/Eng/Management/GeneralPages/Pages/SimpleSearchResult.aspx?objectId=&objectType=&securityType=&searchTerm=BVXV
54 ILS =14.9232USD
http://www.xe.com/currencyconverter/convert/?Amount=54&From=ILS&To=USD
What is NIS? I see on the closing price.
So what am I missing? Did I do it right or wrong?
I do not think a leak. Apprehension and expectation driving the curious into real interest. If it was a leak, in doubt, then must of been good news. lol!
High expectations going forward.
We all in the wait for the European results. Excitement growing.
Brookfield in all sense of the terms should own the other 2% and take the company private from an investors stand point of view or should I say my point of view.
Opinion
Very truthful opinion.
IHUB has those infrequent issues with their server for as long as I have been hanging around. Good days and bad days server.
Looks like promo is in motion.
TXMD. FDA approval or disapproval May 7th.
https://www.therapeuticsmd.com/research/tx004hr
Vaginal drug for pain during the deed and dryness. Looks very promising for approval.
Looks like a good pocket change only investment. Risk verses Gain?
We might be seeing record revenues from operations is my best guess. The rest of the filing will be more of the same old same old in my opinion. Just the numbers will be different. Of course anyone can make a lethal guesstimate presently.
The conference call might prove interesting.
OPINION.
"You should bear in mind that this trial is organized by a European Consortium and the timing is in the hands of the consortium, not BiondVax. Given the number of parties involved it invariably takes longer.
We believe the results should be published in the coming months, we hope even within the coming weeks- but again, it’s out of our hands. As soon as we have the results, of course, we publish straight to the market."
from Kenny Green at Biondvax
http://finance.yahoo.com/quote/BVXV/community?p=BVXV
So in February MNGA had 4.8 million in cash per video.
Cash burn ratio would just about take it down in a few months, unless other revenue sources are contributing, which I believe they are. It is possible the cash burn ratio has subsided some or that ongoing business production is off setting the pull on cash available.
Be nice to know. The word patience is now adopted for this board.
PALDF is messed. Needs to clean up the alphabet in the symbol.
I am positive the results will be positive.
.
.
.
.
.
.
.
.
OPINION.
Gold is spiking on market fears
[Business Insider]
Greg Hoffman
Business InsiderMarch 21, 2017
Gold futures are up 0.8% as investors seek safety from Tuesday's down market. Both the Dow Jones industrial average and S&P 500 are on track for their first declines of at least 1% since October 11.
Gold usually moves higher when there is fear, uncertainty, or volatility in markets.
So far this year, gold has gained 8.5%, after bottoming out in late December.
After a big comeback during the first half of 2016, gold prices fell dramatically from $1387 per ounce in July 2016 to $1127 per ounce in December.
Two of the more popular gold exchange-traded funds are also seeing a bid on Tuesday.
The GLD SPDR Gold Trust ETF is up 0.7% and the GDX Market Vectors Gold Miners ETF, which tracks the performance of the Gold Miners Index is higher by 2.15%.
Gold
http://finance.yahoo.com/news/gold-spiking-market-fears-190900939.html
Technically from a chart stand point. PALDF has been in a golden cross pattern since mid January 2017. (Noted: Not a true golden cross presently) Even with the horrid March 2017 sell off priced in. Share price appears to have stayed above the 200MA average. I myself have low confidence in the share price maintaining the $4.14 (200MA).
My question is that PALDF might be headed for a death cross. Been a lot of turbulence since March 2017. It could keep waning side ways for a long time to come also. That might be the case until the next financials are released, but I would not bet on it personally. Not a very easy task of making a confident judgment call on the share price. Maybe a later date PALDF will become clearer?
Still keeping this one on my watch list regardless.
Opinion
Now that you mentioned it. I am now interested in the filing.
My big question is the cash-burn ratio verses cash available.
Awaiting results of the
European study!!!
Do you hear an echo?
My opinion might mean little or maybe a lot to some, but I believe that 8x8 should be in the $21 stock price range as I post. Believing in that opinion I see no reason not to believe that $32 would be a low ball figure on a buy out. Year over year expansion and revenue growth has been extensive and is projected to repeat the same for some time to come. That is fact. So would $42 a share on a buy out be outlandish on the long term outlook?
I ask myself the question. Would shareholders make out better on a buy out or holding 8x8 over time? Like it was mentioned, whether a buyer comes along or not. 8X8 is still going forward.
That is a good question?
Investment advice with the same words over and over and over again? Sell PTSC before it is to late. You can not deny that. Your using this board for your own personal gain, all the while causing misleading harm to others. Never once have I seen you post to buy PTSC, especially recently before the pop.
You are harming the board followers in my opinion for your own gain.
Maybe if you found another board there be less arguments and less posts deleted by Administration.
Stop with the harm please.
Yes! In the history
I did a little reading on that one. Not enough time to grant you an honest opinion. I found it interesting as I usually have interest with miners, oil and gas type stocks and their business projects.
I have not even touched the financials.
So I grant you no opinion in honesty from me.
Going to monopolize the hot dog vendors. Soon all of New York City will be under MagnaGas as the choice of barbeque fuel. Can you all say "Hot Diggity Dog?"
...
....
...
...
...
...
FICTION. FICTION. FICTION.
DO NOT BELIEVE (HUMOUR)
Dear Patriot Scientific Corporation Stockholder:
On behalf of the Board of Directors and the management of Patriot Scientific Corporation, I'm pleased to extend a personal invitation to you to attend via the internet the annual meeting of stockholders of Patriot Scientific Corporation. We will hold the meeting at 10:00 a.m. Pacific Time on Thursday, May 4, 2017.
We are offering a live webcast of the annual meeting for our stockholders at www.virtualshareholdermeeting.com/PTSC2017 where you will be able to attend the annual meeting and vote electronically.
This booklet includes the Notice of Annual Meeting and the Proxy Statement. The Proxy Statement describes the business to be transacted at the meeting and provides other information about the Company that you should know when you vote your shares.
Thank you for your support and interest in Patriot.
Sincerely,
/s/ Clifford L. Flowers
Clifford L. Flowers
CFO, Interim CEO and Corporate Secretary
March 15, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74104024&symbol=PTSC
Your adjectives are well heard by me. Under a dollar by April 1st, 2017 could be the direction. It is sure obvious that there appears to be a displeasure in the investor sentiment at the moment.
I am just watching at present.
So far everything has been going very well.
I have a gut feeling the results will be positive. I also truly believe this approach will be used for other mutational viruses and other.
BVXV European trial results will be coming out. So far the universal flu vaccine trials have all been successful. Thinly traded.
BVXV, BIONDVAX Pharmaceuticals. http://finance.yahoo.com/quote/BVXV?p=BVXV